Nom du produit:methyl 5-amino-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate
IUPAC Name:methyl 5-amino-4-fluoro-1-methyl-1H-1,3-benzodiazole-6-carboxylate
- CAS：918321-20-7
- Formule moléculaire：C10H10FN3O2
- Pureté：95%
- Numéro de catalogue：CM128230
- Poids moléculaire：223.21
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:918321-20-7
- Formule moléculaire:C10H10FN3O2
- Point de fusion:-
- Code SMILES:O=C(C1=C(N)C(F)=C2N=CN(C)C2=C1)OC
- Densité:
- Numéro de catalogue:CM128230
- Poids moléculaire:223.21
- Point d'ébullition:
- N° Mdl:MFCD26127252
- Stockage:Keep in dark place, store at 2-8°C.
Category Infos
- Benzimidazoles
- Benzimidazole is a benzo derivative of imidazole. It is a kind of bicyclic aromatic organic compounds, which is formed by fusing a six-membered benzene ring and five-membered imidazole at positions 4 and 5 of imidazole ring. It is an important pharmacophore of many biologically active heterocyclic compounds with various pharmacological activities. Benzimidazoles and their derivatives have developed into dynamic heterocyclic systems due to their potency in a variety of biologically active compounds such as anticancer, bactericidal and antiviral drugs. Benzimidazoles are a class of therapeutic motifs with broad relevance in medicinal chemistry.
Column Infos
- Encorafenib plus Binimetinib
- U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
